R&D
Research and Development
ROADMAP
We will develop global femtech drugs that surpass the domestic market through core workforce and financial support with specific goals such as developing subfertility treatments,
entering global markets, expanding the value of new drug pipelines, and strengthening R&D systems.
-
2023
-
Subfertility Treatment Drug GHD101 : Phase 2 Clinical Trial
-
Subfertility Treatment Drug GHD201 : Preclinical Trial
-
Raw materials for health functional foods GHF110, GHF120 : Clinical Trial
-
-
2026
-
Approval of GHF110 and Commercialization : Female Fertility Improvement
-
Approval of GHF110 and Commercialization : Female Menopausal Health Improvement
-
Subfertility Treatment Drug GHD201 : IND Approval and Phase 2 Clinical Trial
-
Expansion of R&D Global Partnership
-
-
2027
-
Subfertility Treatment Drug GHD101 : Phase 3 Clinical Trial
-
Approval of GHF110 and Commercialization : Female Vaginal Health Improvement
-
Approval of GHF110 and Commercialization : Female Menstrual Pain Improvement
-
-
2030
-
Approval of Subfertility Treatment Drug GHD101 and Commercialization
-
Spread Global New Drug (Subfertility Treatment) in Global market
-
Expansion of R&D Value and Investment
-
